Next Article in Journal
The Effect of Tobacco Smoke N-Nitrosamines, NNK and NDEA, and Nicotine, on DNA Mismatch Repair Mechanism and miRNA Markers, in Hypopharyngeal Squamous Cell Carcinoma: An In Vivo Model and Clinical Evidence
Previous Article in Journal
Reducing Unnecessary Biopsies Using Digital Breast Tomosynthesis and Ultrasound in Dense and Nondense Breasts
 
 
Systematic Review

Role of Polygenic Risk Score in Cancer Precision Medicine of Non-European Populations: A Systematic Review

1
Molecular Oncology Cancer Center, Barretos Cancer Hospital, Barretos 14784-400, SP, Brazil
2
Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza 60430-275, CE, Brazil
3
Post-Graduate Program of Pathology, Federal University of Ceara, Fortaleza 60441-750, CE, Brazil
4
Post-Graduate Program in Translational Medicine, Federal University of Ceara, Fortaleza 14784-400, CE, Brazil
5
ICVS/3B’s—PT Government Associate Laboratory, 4704553 Braga, Portugal
6
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4704553 Braga, Portugal
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(8), 5517-5530; https://doi.org/10.3390/curroncol29080436
Received: 6 June 2022 / Revised: 28 July 2022 / Accepted: 1 August 2022 / Published: 4 August 2022
The development of new screening methods and diagnostic tests for traits, common diseases, and cancer is linked to the advent of precision genomic medicine, in which health care is individually adjusted based on a person’s lifestyle, environmental influences, and genetic variants. Based on genome-wide association study (GWAS) analysis, rapid and continuing progress in the discovery of relevant single nucleotide polymorphisms (SNPs) for traits or complex diseases has increased interest in the potential application of genetic risk models for routine health practice. The polygenic risk score (PRS) estimates an individual’s genetic risk of a trait or disease, calculated by employing a weighted sum of allele counts combined with non-genetic variables. However, 98.38% of PRS records held in public databases relate to the European population. Therefore, PRSs for multiethnic populations are urgently needed. We performed a systematic review to discuss the role of polygenic risk scores in advancing precision medicine for different cancer types in multiethnic non-European populations. View Full-Text
Keywords: polygenic risk score; cancer; multiethnic polygenic risk score; cancer; multiethnic
Show Figures

Figure 1

MDPI and ACS Style

Junior, H.L.R.; Novaes, L.A.C.; Datorre, J.G.; Moreno, D.A.; Reis, R.M. Role of Polygenic Risk Score in Cancer Precision Medicine of Non-European Populations: A Systematic Review. Curr. Oncol. 2022, 29, 5517-5530. https://doi.org/10.3390/curroncol29080436

AMA Style

Junior HLR, Novaes LAC, Datorre JG, Moreno DA, Reis RM. Role of Polygenic Risk Score in Cancer Precision Medicine of Non-European Populations: A Systematic Review. Current Oncology. 2022; 29(8):5517-5530. https://doi.org/10.3390/curroncol29080436

Chicago/Turabian Style

Junior, Howard Lopes Ribeiro, Lázaro Antônio Campanha Novaes, José Guilherme Datorre, Daniel Antunes Moreno, and Rui Manuel Reis. 2022. "Role of Polygenic Risk Score in Cancer Precision Medicine of Non-European Populations: A Systematic Review" Current Oncology 29, no. 8: 5517-5530. https://doi.org/10.3390/curroncol29080436

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop